As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

In the video series, Bazhenova and Albrecht discussed the following:

·      Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC

·      EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data

·      Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies

·      EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions

·      Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC

·      Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC

·      Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.